Cargando…

Combined epigenetic/genetic study identified an ALS age of onset modifier

Age at onset of amyotrophic lateral sclerosis (ALS) is highly variable (eg, 27–74 years in carriers of the G(4)C(2)-expansion in C9orf72). It might be influenced by environmental and genetic factors via the modulation of DNA methylation (DNAm) at CpG-sites. Hence, we combined an epigenetic and genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ming, Xi, Zhengrui, Saez-Atienzar, Sara, Chia, Ruth, Moreno, Danielle, Sato, Christine, Montazer Haghighi, Mahdi, Traynor, Bryan J., Zinman, Lorne, Rogaeva, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066440/
https://www.ncbi.nlm.nih.gov/pubmed/33892821
http://dx.doi.org/10.1186/s40478-021-01183-w
_version_ 1783682572054691840
author Zhang, Ming
Xi, Zhengrui
Saez-Atienzar, Sara
Chia, Ruth
Moreno, Danielle
Sato, Christine
Montazer Haghighi, Mahdi
Traynor, Bryan J.
Zinman, Lorne
Rogaeva, Ekaterina
author_facet Zhang, Ming
Xi, Zhengrui
Saez-Atienzar, Sara
Chia, Ruth
Moreno, Danielle
Sato, Christine
Montazer Haghighi, Mahdi
Traynor, Bryan J.
Zinman, Lorne
Rogaeva, Ekaterina
author_sort Zhang, Ming
collection PubMed
description Age at onset of amyotrophic lateral sclerosis (ALS) is highly variable (eg, 27–74 years in carriers of the G(4)C(2)-expansion in C9orf72). It might be influenced by environmental and genetic factors via the modulation of DNA methylation (DNAm) at CpG-sites. Hence, we combined an epigenetic and genetic approach to test the hypothesis that some common single nucleotide polymorphisms (SNPs) at CpG-sites (CpG-SNPs) could modify ALS age of onset. Our genome-wide DNAm analysis suggested three CpG-SNPs whose DNAm levels are significantly associated with age of onset in 249 ALS patients (q < 0.05). Next, genetic analysis validated the association of rs4970944 with age of onset in the discovery (n = 469; P = 0.025) and replication (n = 4160; P = 0.007) ALS cohorts. A meta-analysis of the cohorts combined showed that the median onset in AA-carriers is two years later than in GG-carriers (n = 4629; P = 0.0012). A similar association was observed with its tagging SNPs, implicating a 16 Kb region at the 1q21.3 locus as a modifier of ALS age of onset. Notably, rs4970944 genotypes are also associated with age of onset in C9orf72-carriers (n = 333; P = 0.025), suggesting that each A-allele delays onset by 1.6 years. Analysis of Genotype-Tissue Expression data revealed that the protective A-allele is linked with the reduced expression of CTSS in cerebellum (P = 0.00018), which is a critical brain region in the distributed neural circuits subserving motor control. CTSS encodes cathepsin S protein playing a key role in antigen presentation. In conclusion, we identified a 16 Kb locus tagged by rs4970944 as a modifier of ALS age of onset. Our findings support the role of antigen presenting processes in modulating age of onset of ALS and suggest potential drug targets (eg, CTSS). Future replication studies are encouraged to validate the link between the locus tagged by rs4970944 and age of onset in independent ALS cohorts, including different ethnic groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01183-w.
format Online
Article
Text
id pubmed-8066440
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80664402021-04-26 Combined epigenetic/genetic study identified an ALS age of onset modifier Zhang, Ming Xi, Zhengrui Saez-Atienzar, Sara Chia, Ruth Moreno, Danielle Sato, Christine Montazer Haghighi, Mahdi Traynor, Bryan J. Zinman, Lorne Rogaeva, Ekaterina Acta Neuropathol Commun Research Age at onset of amyotrophic lateral sclerosis (ALS) is highly variable (eg, 27–74 years in carriers of the G(4)C(2)-expansion in C9orf72). It might be influenced by environmental and genetic factors via the modulation of DNA methylation (DNAm) at CpG-sites. Hence, we combined an epigenetic and genetic approach to test the hypothesis that some common single nucleotide polymorphisms (SNPs) at CpG-sites (CpG-SNPs) could modify ALS age of onset. Our genome-wide DNAm analysis suggested three CpG-SNPs whose DNAm levels are significantly associated with age of onset in 249 ALS patients (q < 0.05). Next, genetic analysis validated the association of rs4970944 with age of onset in the discovery (n = 469; P = 0.025) and replication (n = 4160; P = 0.007) ALS cohorts. A meta-analysis of the cohorts combined showed that the median onset in AA-carriers is two years later than in GG-carriers (n = 4629; P = 0.0012). A similar association was observed with its tagging SNPs, implicating a 16 Kb region at the 1q21.3 locus as a modifier of ALS age of onset. Notably, rs4970944 genotypes are also associated with age of onset in C9orf72-carriers (n = 333; P = 0.025), suggesting that each A-allele delays onset by 1.6 years. Analysis of Genotype-Tissue Expression data revealed that the protective A-allele is linked with the reduced expression of CTSS in cerebellum (P = 0.00018), which is a critical brain region in the distributed neural circuits subserving motor control. CTSS encodes cathepsin S protein playing a key role in antigen presentation. In conclusion, we identified a 16 Kb locus tagged by rs4970944 as a modifier of ALS age of onset. Our findings support the role of antigen presenting processes in modulating age of onset of ALS and suggest potential drug targets (eg, CTSS). Future replication studies are encouraged to validate the link between the locus tagged by rs4970944 and age of onset in independent ALS cohorts, including different ethnic groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01183-w. BioMed Central 2021-04-23 /pmc/articles/PMC8066440/ /pubmed/33892821 http://dx.doi.org/10.1186/s40478-021-01183-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Ming
Xi, Zhengrui
Saez-Atienzar, Sara
Chia, Ruth
Moreno, Danielle
Sato, Christine
Montazer Haghighi, Mahdi
Traynor, Bryan J.
Zinman, Lorne
Rogaeva, Ekaterina
Combined epigenetic/genetic study identified an ALS age of onset modifier
title Combined epigenetic/genetic study identified an ALS age of onset modifier
title_full Combined epigenetic/genetic study identified an ALS age of onset modifier
title_fullStr Combined epigenetic/genetic study identified an ALS age of onset modifier
title_full_unstemmed Combined epigenetic/genetic study identified an ALS age of onset modifier
title_short Combined epigenetic/genetic study identified an ALS age of onset modifier
title_sort combined epigenetic/genetic study identified an als age of onset modifier
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066440/
https://www.ncbi.nlm.nih.gov/pubmed/33892821
http://dx.doi.org/10.1186/s40478-021-01183-w
work_keys_str_mv AT zhangming combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT xizhengrui combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT saezatienzarsara combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT chiaruth combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT morenodanielle combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT satochristine combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT montazerhaghighimahdi combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT traynorbryanj combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT zinmanlorne combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier
AT rogaevaekaterina combinedepigeneticgeneticstudyidentifiedanalsageofonsetmodifier